Zoetis Inc. (ZTS) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 1.48B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $1.48B | (m) | (m) |
| 2026-03-31 | (m) | (m) | $1.94B | (m) | (m) |
| 2025-12-31 | (m) | (m) | $2.45B | (m) | (m) |
| 2025-09-30 | (m) | (m) | $2.08B | (m) | (m) |
| 2025-06-30 | (m) | (m) | $1.44B | (m) | (m) |
| 2025-03-31 | (m) | (m) | $1.72B | (m) | (m) |
| 2024-12-31 | (m) | (m) | $1.99B | (m) | (m) |
| 2024-09-30 | (m) | (m) | $1.71B | (m) | (m) |
| 2024-06-30 | (m) | (m) | $1.57B | (m) | (m) |
| 2024-03-31 | (m) | (m) | $1.98B | (m) | (m) |
| 2023-12-31 | (m) | (m) | $2.04B | (m) | (m) |
| 2023-09-30 | (m) | (m) | $1.75B | (m) | (m) |
| 2023-06-30 | (m) | (m) | $1.72B | (m) | (m) |
| 2023-03-31 | (m) | (m) | $2.11B | (m) | (m) |
| 2022-12-31 | (m) | (m) | $3.58B | (m) | (m) |
| 2022-09-30 | (m) | (m) | $2.51B | (m) | (m) |
| 2022-06-30 | (m) | (m) | $2.65B | (m) | (m) |
| 2022-03-31 | (m) | (m) | $3.13B | (m) | (m) |
| 2021-12-31 | (m) | (m) | $3.48B | (m) | (m) |
| 2021-09-30 | (m) | (m) | $3.27B | (m) | (m) |
| 2021-06-30 | (m) | (m) | $3.66B | (m) | (m) |
| 2021-03-31 | (m) | (m) | $3.60B | (m) | (m) |
| 2020-12-31 | (m) | (m) | $3.60B | (m) | (m) |
| 2020-09-30 | (m) | (m) | $3.65B | (m) | (m) |
| 2020-06-30 | (m) | (m) | $3.35B | (m) | (m) |
| 2020-03-31 | (m) | (m) | $1.95B | (m) | (m) |
| 2019-12-31 | (m) | (m) | $1.93B | (m) | (m) |
| 2019-09-30 | (m) | (m) | $1.81B | (m) | (m) |
| 2019-06-30 | (m) | (m) | $1.75B | (m) | (m) |
| 2019-03-31 | (m) | (m) | $1.73B | (m) | (m) |
| 2018-12-31 | (m) | (m) | $1.60B | (m) | (m) |
| 2018-09-30 | (m) | (m) | $1.29B | (m) | (m) |
| 2018-06-30 | (m) | (m) | $1.56B | (m) | (m) |
| 2018-03-31 | (m) | (m) | $1.65B | (m) | (m) |
| 2017-12-31 | (m) | (m) | $1.56B | (m) | (m) |
| 2017-10-01 | (m) | (m) | $1.98B | (m) | (m) |
| 2017-07-02 | (m) | (m) | $705.00M | (m) | (m) |
| 2017-04-02 | (m) | (m) | $629.00M | (m) | (m) |
| 2016-12-31 | (m) | (m) | $727.00M | (m) | (m) |
| 2016-10-02 | (m) | (m) | $651.00M | (m) | (m) |
| 2016-07-03 | (m) | (m) | $658.00M | (m) | (m) |
| 2016-04-03 | (m) | (m) | $675.00M | (m) | (m) |
| 2015-12-31 | (m) | (m) | $1.15B | (m) | (m) |
| 2015-09-27 | (m) | (m) | $592.00M | (m) | (m) |
| 2015-06-28 | (m) | (m) | $544.00M | (m) | (m) |
| 2015-03-29 | (m) | (m) | $559.00M | (m) | (m) |
| 2014-12-31 | (m) | (m) | $882.00M | (m) | (m) |
| 2014-09-28 | (m) | (m) | $598.00M | (m) | (m) |
| 2014-06-29 | (m) | (m) | $578.00M | (m) | (m) |
| 2014-03-30 | (m) | (m) | $506.00M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $610.00M | (m) | (m) |
| 2013-09-29 | (m) | (m) | $389.00M | (m) | (m) |
| 2013-06-30 | (m) | (m) | $369.00M | (m) | (m) |
| 2013-03-31 | (m) | (m) | $468.00M | (m) | (m) |
| 2012-12-31 | (m) | (m) | $317.00M | (m) | (m) |
| 2012-09-30 | (m) | (m) | $133.00M | (m) | (m) |
| 2012-07-01 | (m) | (m) | $106.00M | (m) | (m) |
| 2012-04-01 | (m) | (m) | $113.00M | (m) | (m) |
| 2011-12-31 | (m) | (m) | $79.00M | (m) | (m) |
| 2010-12-31 | (m) | (m) | $63.00M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |